These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23427388)

  • 1. Randomized controlled multicenter clinical trial for integrated treatment of community-acquired pneumonia based on traditional Chinese medicine syndrome differentiation.
    Li J; Yu X; Li S; Wang H; Bai Y; Wang M; Sun Z; Zhang W; Zhou Z; Jia X; Zhou Q
    J Tradit Chin Med; 2012 Dec; 32(4):554-60. PubMed ID: 23427388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated traditional Chinese and conventional medicine in treatment of severe community-acquired pneumonia: study protocol for a randomized placebo-controlled trial.
    Wang H; Li J; Yu X; Li SY
    Trials; 2018 Nov; 19(1):620. PubMed ID: 30419961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional study of the clinical characteristics of hospitalized children with community-acquired pneumonia in eight eastern cities in China.
    Wang XF; Liu JP; Shen KL; Ma R; Cui ZZ; Deng L; Shang YX; Zhao DY; Wang LB; Wan LY; Sun YQ; Li YN; Jiang ZY; Xu H; Li XM; Wu ZQ; Liu ZL; Hu YH; Huang Y; He CH; Zhang H; Jiang YH; Liu H; Wang Z
    BMC Complement Altern Med; 2013 Dec; 13():367. PubMed ID: 24364897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia.
    Zhao X; Wu JF; Xiu QY; Wang C; Zhang DP; Huang JA; Xie CM; Sun SH; Lv XJ; Si B; Xiao ZK; Zhang YY
    Diagn Microbiol Infect Dis; 2014 Oct; 80(2):141-7. PubMed ID: 25130297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.
    Donowitz GR; Brandon ML; Salisbury JP; Harman CP; Tipping DM; Urick AE; Talbot GH
    Clin Ther; 1997; 19(5):936-53. PubMed ID: 9385482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia].
    Jiang XT; Du YP; Deng LP
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1876-8. PubMed ID: 15631797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.
    Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A
    JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
    Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
    J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia in Japan.
    Yamamoto Y; Watanabe A; Goto H; Matsushima T; Abe S; Aoki N; Shimokata K; Mikasa K; Niki Y; Kohno S
    J Infect Chemother; 2012 Aug; 18(4):544-51. PubMed ID: 22618270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokine changes in community-acquired pneumonia in elderly and intervention of traditional Chinese medicine].
    Ye S; Gong G; Zheng H; Hu G; Xia T
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1486-9. PubMed ID: 20822027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
    Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
    J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol].
    Nie HM; Gao YQ; Chen JJ
    Zhong Xi Yi Jie He Xue Bao; 2011 Apr; 9(4):365-73. PubMed ID: 21486548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traditional Chinese versus integrative treatment in elderly patients with isolated systolic hypertension: a multicenter, randomized, double-blind controlled trial.
    Li H; Liu LT; Zhao WM; Liu JG; Yao MJ; Han YX; Shen YP; Liu XD; Liu L; Wang XM; Cai LL; Guan J
    Zhong Xi Yi Jie He Xue Bao; 2010 May; 8(5):410-6. PubMed ID: 20456838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
    Nicholson SC; Welte T; File TM; Strauss RS; Michiels B; Kaul P; Balis D; Arbit D; Amsler K; Noel GJ
    Int J Antimicrob Agents; 2012 Mar; 39(3):240-6. PubMed ID: 22230331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
    Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
    PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
    Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
    Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.